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Abstract
The synthesis and evaluation of several benzothiazole based compounds are described in an
attempt to identify novel dual-acting 5HT1A receptor and SERT inhibitors as new antidepressants.
Binding affinities at the 5HT1A receptor and the serotonin transporter do not appear to be
congruent and other areas of the binding sites would need to be explored in order to improve
binding simultaneously at both sites. Compounds 20 and 23 show moderate binding affinity at the
5HT1A receptor and the SERT site and thus, have the potential to be further explored as dual-
acting agents. In addition, compound 20 binds with low affinity to the dopamine transporter
(DAT), the norepinephrine transporter (NET) and 5HT2C receptor, which are desirable properties
as selectivity for SERT (and not DAT or NET) is associated with an absence of cardiovascular
side-effects.
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1. Introduction
According to the National Institute of Mental Health (NIMH), depressive disorders affect
approximately 19 million American adults or 9.5% of the U.S. population age 18 and older
in a given year. This includes major depressive disorder, dysthymic disorder, and bipolar
disorder [1]. The most widespread treatment option for depression is the use of
antidepressants. Selective serotonin reuptake inhibitors (SSRIs) such as Prozac (1), have
changed the landscape of antidepressant therapy for some time now and have several
advantages over their predecessors, the tricyclic antidepressants (TCAs). The superior
clinical profile of SSRIs is said to be related to their overall selectivity resulting in the
absence of cardiovascular disease (<0.0003%) and a high therapeutic index [2]. However,
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antidepressants in general, including SSRIs suffer from a variety of drawbacks including the
fact that up to a third of patients do not respond to treatment. There is also a delay of about 4
– 6 weeks in the onset of action of SSRIs. One hypothesis suggests that the delay in the
onset of action is due to a negative feedback control exerted by 5HT1A autoreceptors on
nerve terminal 5HT release [3]. According to this hypothesis, onset of action is initiated only
when this impulse flow is restored following desensitization of 5HT1A autoreceptors and
coincident increases in postsynaptic 5HT levels are achieved. Clinical proof of this
hypothesis has been suggested in studies that found a significant augmentation of the effect
of SSRIs when the β-adrenergic/5HT1A receptor antagonist pindolol was co-administered
with SSRI treatment [4]. Indeed, the FDA has recently approved the first drug developed on
the basis of this hypothesis, vilazodone (Viibryd®), for the treatment of depression [5].
Vilazodone has been demonstrated to act as an inhibitor of SERT and a partial agonist at the
5HT1A receptor, binding with very high affinities at these sites [6] (Table 1). Its binding
affinities at other receptors such as DAD2 and 5HT2A receptors, DAT and NET are said to
be low and this selectivity appears to support the basis for its superior therapeutic profile [7–
9].
As part of our on-going drug discovery effort to identify new leads for the treatment of
mental illnesses, we evaluated several benzothiazoles at DA and 5HT receptors [10] (Table
1). Further screening at other CNS receptors has led to the identification of compounds 3
and 6 as SERT inhibitors as well as 5HT1A receptor ligands (Chart 1). Based on the
pharmacological properties of various CNS receptors, we have hypothesized that an agent
which antagonizes the 5HT1A receptor, inhibits SERT and does not interact avidly with
DAT, NET, DA D2-like subtypes, 5HT2C and H1 receptors will have a potentially superior
therapeutic profile as novel antidepressants [11–17]. Thus, the aim of this research was to
study the structure-activity relationships of newly designed benzothiazoles in order to
understand the contributions of the component parts towards selectivity for the 5HT1A
receptor and inhibition of SERT.
2. Chemistry
The syntheses of compounds 3 – 6 were previously reported [10]. To obtain key alkylating
agents 27, 28, 34 and 35, the method of Chikashita et al [18] as reported in Peprah, et al [10]
was followed, taking advantage of the reactivity of 2-lithiobenzothiazole to various
electrophiles. Alkylating agent 2-(3-chloropropyl)benzo[d]thiazole 27 was prepared by
reacting 2-aminothiophenol 24 and 4-chlorobutanoyl chloride 25 in toluene, followed by
purification on silica gel. Alkylating agent 2-(4-chlorobutyl)benzo[d]thiazole 28 was
obtained in a similar manner using 5-chloropentanoyl chloride as described in Scheme 1.
Target compounds 7 – 12, were obtained by coupling each alkylating agent 27 and 28 with
different amines in the presence of K2CO3 and KI (Scheme 2).
Alkylating agent, 1-(benzo[d]thiazol-2-yl)-4-iodobutan-1-one 34 was prepared by a two-step
transformation starting from benzothiazole 29. Deprotonation of 29 with n-BuLi in THF at
−78 °C was followed by treatment with lactone 30 to obtain 1-(benzo[d]thiazol-2-yl)-4-
hydroxybutan-1-one 32. Treatment of alcohol 32 with I2 in the presence of imidazole and
Ph3P in CH2Cl2 afforded 1-(benzo[d]thiazol-2-yl)-4-iodobutan-1-one 34. Using the same
procedure, alkylating agent, 1-(benzo[d]thiazol-2-yl)-5-iodopentan-1-one 35 was
synthesized, as described in Scheme 3. Compounds 13–23 were synthesized by reacting
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each alkylating agent, 34 and 35 with different amines in the presence of K2CO3 and KI in
CH3CN as solvent as shown in Scheme 4.
3. Results and Discussion
During a search for new atypical antipsychotic agents [10], we synthesized and screened
several compounds, among which were compounds 3 – 6, for their binding affinities at
dopamine D2, D3 and D4 receptor subtypes as well as serotonin 5HT1A, 5HT2A and 5HT2C
receptors. Screening of these compounds at additional 5HT receptors and at SERT showed
that compounds 3, 4 and 6 have affinity to SERT as well as the 5HT1A receptor (Table 1).
This observation provided the impetus for the current study to design new agents and
conduct a structure-activity relationship study of benzothiazole-based compounds as new
potential dual-acting antidepressants.
Compound 3 is a benzothiazole linked by a propyl chain to a 4-chlorophenyl
homopiperazine moiety. Compound 4 differs from 3 by a methylene group which extends
the propyl to a butyl linkage. This modification has resulted in minimal change in binding at
both the 5HT1A receptor and SERT. Insertion of a carbonyl group in compound 3 to form 5
or in 4 to form 6, resulted in loss of binding affinity to the 5HT1A receptor. However, at
SERT, compound 5 binds with over 6-fold increase compared to 3 and compound 6 binds
with the same affinity compared to 4 suggesting that the presence of the carbonyl group has
a mixed effect on binding to the 5HT1A receptor and the SERT site.
The next design strategy was to replace the 4-chlorophenyl homopiperazine moiety with
arylcycloalkyl amine pharmacophores with affinity to CNS receptors including the 5HT1A
receptor. The results are recorded in Table 2. Compounds 7 and 8 are obtained by
replacement of the homopiperazine ring in compounds 3 and 4 respectively with a
piperazine ring. Compound 7 binds with less affinity to both the 5HT1A receptor and SERT
as compared to compound 3, suggesting that the homopiperazine ring is better tolerated at
these receptors when the chain length is three. Compound 8 on the other hand, showed about
a 3-fold increase in binding to the 5HT1A receptor but a 2.6-fold decrease in binding at the
SERT site. Comparing the binding affinities of 7 and 8 suggests that increasing chain length
from 3 to 4 with the piperazine ring in place, is better tolerated at both receptors.
Interestingly, the carbon chain length in vilazodone is 4 as well. Considering compounds 9 –
11, the contributions of 4-chlorophenyl piperidinol, 2-(piperazin-1-yl)pyrimidine and
tetrahydroisoquinoline moieties respectively, were probed by substituting them in place of
the 4-chlorophenyl piperazine moiety in 8. Evaluation of compound 9, with the 4-
chlorophenyl piperidinol moiety resulted in significant decreases in binding at both the
5HT1A receptor and SERT.
In previous publications, [17, 19] we observed that 2-(piperazin-1-yl)pyrimidine moiety
enhanced binding affinity to the 5HT1A receptor. Replacing the 4-chlorophenyl moiety in 8
with the pyrimidinyl moiety to form 10 led to an increase of over 13-fold binding affinity
over compound 8. In a similar manner, replacement of the 4-chlorophenyl piperazine with a
tetrahydroisoquinoline ring produced compound 11 and about 18-fold increase in the
binding affinity to the 5HT1A receptor. Unfortunately, both compounds have significantly
less binding at the SERT. Compound 12 in which the 4-chlorophenyl moiety is replaced by
an isoindole ring, had only moderate binding at both receptors.
Compound 13 was obtained by insertion of a carbonyl group into compound 7 and
compound 14 is the unsubstituted analog of 13. Evaluation of 13 and 14 showed that the
presence of the carbonyl group produced a decrease on binding affinity at both the 5HT1A
receptor and SERT as shown in Table 3. Interestingly, the absence of N-1 from the
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piperazine ring in compound 14 to form 15 improved the binding affinity at both 5HT1A and
SERT. Replacement of the phenyl group in compound 14 with a 2-pyrimidinyl ring to form
16, also led to an improvement in binding affinity to the 5HT1A receptor as expected.
However, compound 16 has little or no affinity to SERT.
Replacement of the 2-(piperazin-1-yl)pyrimidine moiety in compound 16 with 5-chloro-1-
(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one to form compound 17 resulted in
diminished binding to the 5HT1A receptor and only a low binding affinity to SERT. Chain
extension by one methylene group and exploration of two arylcycloalkyl amine groups; 1-
phenyl-1,3,8-triazaspiro[4.5]decan-4-one (Compound 18) and isoindoline (Compound 19)
by replacing the 4-chlorophenyl homopiperazine moiety did not result in significant
improvements in binding affinity at 5HT1A and SERT.
Compound 20 was obtained by inserting a carbonyl group between the benzothiazole ring
and the first methylene group in compound 8. Evaluation of its binding affinities showed
that binding to the 5HT1A receptor was enhanced by over 3-fold and to SERT by over 2-
fold. In compound 21, the 4-chlorophenyl ring is replaced by 2,6-pyrimidinyl ring. As
expected, the binding to the 5HT1A receptor again increased about 8-fold over compound 20
and more than 25-fold over compound 8. Surprisingly, compound 21 demonstrated little or
no binding to SERT. The contribution of the 4-chloro group to binding affinity was
investigated by evaluating compound 22. The presence of the chloro group imparted a 7.9
fold increase in the binding affinity at the 5HT1A receptor but binding to the SERT site
showed over 3-fold decrease. This observation suggests the possibility that substituents on
the phenyl ring may affect binding to these receptors. Finally, when the piperazine ring in
compound 22 was replaced by a piperidine ring to form compound 23, binding affinity
decreased by 2-fold at the 5HT1A receptor but increased to 64 nM at the SERT site.
In addition to the evaluations at the 5HT1A and SERT, it was also of interest to investigate
the binding of the compounds at receptors which might influence antipsychotic and
antidepressant pharmacology and/or side effects, including 5HT2A, 5HT7, 5HT2C, D2 and
D4 receptors, H1, DAT and NET. Only two compounds, 7 and 23 (Ki = 36 and 3.4 nM
respectively) bind with moderately high affinity to the 5HT2A receptor. Similarly, only
compounds 11 and 22 bind with moderately high affinity at the 5HT7 receptor (Ki = 35.6
and 62.6 nM respectively). At the 5HT2C receptor, none of the compounds has affinity better
than 1000 nM which is desirable as high affinity to this receptor may be associated with
weight gain [19–21]. We have previously presented a set of criteria for compounds to be
considered for further screening as new antipsychotic agents [19]. These include binding to
dopamine D2 receptor within 10 < Ki < 150 nM range, high affinity for D4 receptor (Ki ≤ 10
nM), high affinity for 5HT1A and 5HT2A receptors and a low affinity for 5HT2C and H1
receptors. Only compounds 10, 11 and 18 meet the dopamine D2 binding requirement and
will be further screened at relevant receptors. At the D4 receptor, only compounds 8 and 10
(Ki = 4.0 and 0.8 nM respectively) have binding affinity better than 10 nM. Interestingly,
compound 10 turned out to be the most potent and D4 selective agent (with selectivity index,
D2/D4 = 33.1) among the compounds evaluated.
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Overall, the binding affinities at the 5HT1A receptor and the SERT site do not appear to be
congruent and other areas of the binding sites would need to be explored in order to improve
binding simultaneously at both sites. Only compounds 20 and 23 demonstrate
simultaneously relatively moderate affinity binding at both 5HT1A receptor and the SERT
site and thus have the potential to be further explored as dual-acting agents. Compound 20
shows low affinity for DAT, NET and 5HT2C receptor, which are desirable properties as
selectivity for SERT (and not DAT or NET) is associated with an absence of cardiovascular
problems. The low affinity for 5HT2C is also desirable because of its association with weight
gain and type II diabetes [20]. The moderate affinity for the H1 receptor is undesirable for
the same reasons indicated for the 5HT2C receptor [21]. For compound 23, there is a need to
decrease the binding affinity to NET and the H1 receptor for the same reasons stated. Efforts
in this direction are ongoing. Plans are also ongoing to conduct functional assays to
determine whether compounds with high affinity to the 5HT1A receptor are agonists or
antagonists.
5. Experimental
5.1 Reagents and general procedures
Melting points were determined on a Gallenkamp (UK) apparatus and are uncorrected. 1H
NMR spectra were obtained on a Varian 300 MHz Mercury Spectrometer. Elemental
analyses were carried out by Atlantic Microlab, Inc., Norcross, GA, and are within 0.4% of
theory unless otherwise noted. Flash chromatography was performed on Combi-Flash
(Teledyne Isco) using RediSep columns. N,N Dimethylformamide was distilled from CaSO4
and stored over 4Å molecular sieves. Starting materials were obtained from Sigma-Aldrich
and were used without further purification.
5.2. General procedure for synthesis of alkylating agents (27, 28)
To a solution of 2-aminothiophenol (5 g, 39.9 mmol) in toluene (100 mL), 5-chlorobutanoyl
chloride (25) or 5-chloropentanoyl chloride (26) (43.9 mmol) was added drop wise over a 15
min period and during the addition, an off-white precipitate was formed. The reaction
mixture was stirred at room temperature (rt) overnight, then water (100 mL) was added, the
two layers were separated and the aqueous layer was extracted with EtOAc (2 × 100 mL).
The combined organic extract was washed with water (100 mL) and saturated NaCl
solution, dried over Na2SO4 and concentrated in vacuo. The crude product was purified on
Combiflash using EtOAc/Hexanes, to afford 2-(3-chloropropyl)benzo-[d]thiazole 27 or 2-(4-
chlorobutyl)benzo[d]thiazole 28 as an oily liquid.
5.2.1 2-(3-Chloropropyl)benzo[d]thiazole (27)—Oily liquid (72% yield). 1H NMR
(CD3OD): δ 8.14 (d, 1H, J = 4.1 Hz), 8.02 (d, 1H, J = 4.1 Hz), 7.72-7.59 (m, 2H), 3.64-3.57
(m, 2H), 3.38-3.28 (m, 2H), 1.95-1.86 (m, 2H).
5.2.2 2-(4-Chlorobutyl)benzo[d]thiazole (28)—Oily liquid (56% yield). 1H NMR
(CDCl3) : δ 7.98-7.95 (m, 1H), 7.85-7.82 (m, 1H), 7.48-7.42 (m, 1H), 7.37-7.32 (m, 1H),
3.60 (t, 2H, J = 7.5 Hz), 3.15 (t, 2H, J = 7.5 Hz), 2.09-1.97 (m, 2H), 1.95-1.90 (m, 2H).
5.3. General procedure for synthesis of alkylating agents (34, 35)
A stirred solution of benzo[d]thiazole 29 (10 g, 74 mmol) in dry THF (37 mL) under N2 was
cooled to −78 °C (dry ice /acetone bath) and 10% excess of n-BuLi (37 mL 1M solution in
THF) was added in a drop-wise manner. Just before the addition was completed, the solution
gave rise to a clear orange colored solution. Thereafter, a solution of lactone, 30 (7.0 g, 81
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mmol) or 31 (8.14 g, 81 mmol) in dry THF (37 mL) was added to the reaction mixture at
−78 °C, and the mixture was stirred at −78 °C for 1h. After removal of the cold bath, the
reaction mixture was continuously stirred for 30 minutes and then quenched with a large
excess of 0.1 M HCl (300 mL). The aqueous mixture was extracted with EtOAc (3 × 150
mL) and the combined organic extracts was washed with H2O (2 × 100 mL) and saturated
NaCl (100 mL) and dried over Na2SO4. The solution was concentrated in vacuo, the crude
product was dissolved in EtOAc (50 mL), hexane (200 mL) was added to precipitate an
orange solid. The precipitate was filtered, washed with 10% EtOAc/Hexane (200 mL) and
dried in vacuo to obtain the pure products, 1-(benzo[d]thiazol-2-yl)-4-hydroxybutan-1-one
32 and 1-(benzo[d]thiazol-2-yl)-5-hydroxypentan-1-one 33, as solids.
5.3.1. 1-(Benzo[d]thiazol-2-yl)-4-hydroxybutan-1-one (32)—Solid (49 % yield), mp:
93–94 °C. 1H NMR (CDCl3) : δ 8.20-8.17 (m, 1H), 8.00-7.97 (m, 1H), 7.61-7.51 (m, 2H),
3.79-3.75 (m, 2H), 3.41 (t, 2H, J = 6.9 Hz), 2.14-2.05 (m, 2H).
5.3.2. 1-(Benzo[d]thiazol-2-yl)-5-hydroxypentan-1-one (33)—Solid (37% yield),
mp: 81–83 °C; 1H NMR (CDCl3) : δ 8.18 (dd, 1H, J = 1.8, 6.9 Hz), 7.97 (dd, 1H, J = 1.5,
7.2 Hz), 7.62-7.52 (m, 2H), 3.71 (t, 2H, J = 6.3 Hz), 3.40 (t, 2H, J = 7.2 Hz), 2.00-1.88 (m,
2H), 1.76-1.67 (m, 2H).
To a solution of TPP (3.12 g, 11.9 mmol), imidazole (810 mg) in CH2Cl2 (30 mL) was
added iodine (3.02 g, 11.9 mmol) at 0–5 °C. The reaction mixture was stirred at 0–5 °C for
30 minutes and a solution of 1-(benzo[d]thiazol-2-yl)-4-hydroxybutan-1-one (32) (1.9 g, 8.6
mmol) or 1-(benzo[d]thiazol-2-yl)-5-hydroxypentan-1-one (33) (2.0 g, 8.5 mmol) in CH2Cl2
(15 mL) was added drop wise for 5 min. The reaction mixture was stirred at 0–5 °C for
another 30 min, and then the ice bath was removed and stirring continued at rt for 12 h.
When TLC showed the reaction was complete, the reaction mixture was treated with water
(100 mL), the two layers were separated, and the aqueous layer was extracted with CH2Cl2
(2 × 50 mL). The combined organic extracts was washed with water (2 × 100 mL) and 10%
sodium thiosulfate solution (50 mL), water (100 mL) then saturated aqueous NaCl solution
(75 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was further
purified on Combiflash using EtOAc/Hexane (1 : 9) to obtain the pure product as 1-
(benzo[d]thiazol-2-yl)-4-iodobutan-1-one (34) or 1-(benzo[d]thiazol-2-yl)-5-iodopentan-1-
one (35) as a solid.
5.3.3 1-(Benzo[d]thiazol-2-yl)-4-iodobutan-1-one (34)—Solid (43 % yield), mp: 91–
92 °C; 1H NMR (CDCl3): δ 8.21-8.18 (m, 1H), 8.00-7.97 (m, 1H), 7.62-7.52 (m, 2H), 3.45
(t, 2H, J = 6.9 Hz), 3.34 (t, 2H, J = 6.6 Hz), 2.35 (q, 2H, J = 6.90 Hz).
5.3.4 1-(Benzo[d]thiazol-2-yl)-5-iodopentan-1-one (35)—Solid (61 % yield), mp:
88–89 °C; 1H NMR (CDCl3) : δ 8.20 (dd, 1H, J = 1.5, 7.8 Hz), 8.98 (dd, 1H, J = 1.2, 7.8
Hz), 7.61-7.51 (m, 2H), 3.34-3.23 (m, 4H), 2.02-1.90 (m, 4H).
5.4. General alkylation procedure for compounds (7–12)
A mixture of 2-(3-chloropropyl)benzo[d]thiazole (27) (1.33 mmol), or 2-(4-
chlorobutyl)benzo[d]thiazole (28), the appropriate amine, (1.33 mmol), KI (100 mg),
K2CO3 (13.3 mmol), and CH3CN (15 mL) was heated to reflux for 12-24 h. The mixture
was cooled to room temperature and then loaded onto a cartridge and purified by flash
chromatography using EtOAc and hexane (9:1) to give the desire products.
5.4.1 2-(3-(4-(4-Chlorophenyl)piperazin-1-yl)propyl)benzo[d]thiazole
hydrochloride (7)—Yield (32 %), mp: 158–160 °C; 1H NMR (CD3OD): δ 7.94–8.01 (m,
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2H), 7.52–7.57 (m, 1H), 7.43–7.49 (m, 1H), 7.26 (dd, 2H, J = 6.6, 2.4 Hz), 7.01 (dd, 2H, J =
6.8, 2.4 Hz), 3.62–3.94 (m, 4H), 3.34–3.42 (m, 4H), 3.29–3.32 (m, 4H), 2.39–2.46 (m, 2H).
Anal.Calcd for C20H24Cl3N3S.0.6 H2O: C, 52.72; H, 5.31; N, 9.22. Found: C, 52.60; H,
5.57; N, 9.15.
5.4.2. 2-(4-(4-(4-Chlorophenyl)piperazin-1-yl)butyl)benzo[d]thiazole (8)—Yield
(20%), mp: 104–106 °C; 1H NMR (CDCl3) : δ 7.98-7.95 (m, 1H), 7.86-7.83 (m, 1H),
7.48-7.43 (m, 1H), 7.38-7.35 (m, 1H), 7.20 (dd, 2H, J = 2.4, 9.3 Hz), 6.84 (dd, 2H, J = 2.4,
9.0 Hz), 3.19-3.14 (m, 6H), 2.58 (t, 2H, J = 5.1 Hz), 2.45 (t, 2H, J = 7.5 Hz), 1.97-1.92 (m,
2H), 1.70-1.65 (m, 2H). Anal. Calcd for C21H24ClN3S: C, 65.35; H, 6.27; N, 10.89. Found:
C, 65.11; H, 6.05; N, 10.71.
5.4.3. 2-(4-(4-(4-Chlorophenyl)piperazin-1-yl)butyl)benzo[d]thiazole
(8)hydrochloride—Yield (48 %), mp: 214–216 °C. 1H NMR (CD3OD): δ 8.22 (d, 1H, J =
8.1 Hz), 8.07 (d, 1H, J = 8.1 Hz), 7.79-7.74 (m, 1H), 7.70-7.65 (m, 1H), 7.27 (d, 2H, J = 8.4
Hz), 7.02 (d, 2H, J = 9 Hz), 3.91-3.63 (m, 4H), 3.52-3.46 (m, 2H), 3.40-3.20 (m, 6H),
2.18-1.98 (m, 4H). Anal. Calcd for C21H26Cl3N3S.H2O: C, 51.72; H, 5.37; N, 8.62. Found:
C, 51.61; H, 5.68; N, 8.35.
5.4.4. 1-(4-(Benzo[d]thiazol-2-yl)butyl)-4-(4-chlorophenyl)piperidin-4-ol (9)—
Yield (18%), mp: 143–145 °C; 1H NMR (CDCl3) : δ 7.97-7.94 (m, 1H), 7.86-7.83 (m, 1H),
7.48-7.42 (m, 3H), 7.37-7.26 (m, 3H), 3.16 (t, 2H, J = 7.8 Hz), 2.98-2.88 (m, 2H), 2.60-2.52
(m, 4H), 2.30-2.18 (m, 2H), 1.97-1.90 (m, 2H), 1.80-1.70 (m, 4H). Anal. Calcd for
C22H25ClN2OS: C, 65.90; H, 6.28; N, 6.99. Found: C, 65.16; H, 6.17; N, 6.91.
5.4.5 2-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-benzo[d]thiazole
hydrochloride (10)—The product was converted into HCl salt, followed by crystallization
from MeOH-Et2O to give the pure compound. Yield (19%), mp: 236–237 °C; 1H NMR
(DMSO-d6): δ 11.44 (brs, 1H), 8.44 (d, 2H, J = 5.1 Hz), 8.04 (d, 1H, J = 8.1 Hz), 7.91 (d,
1H, J = 8.1 Hz), 7.50-7.44 (m, 1H), 7.41-7.36 (m, 1H), 6.77 (t, 1H, J = 5.1 Hz), 4.66 (d, 2H,
J = 14.4 Hz), 3.53-3.42 (m, 4H), 3.19-3.10 (m, 4H), 3.04-2.97 (2H, m), 1.88-1.82 (m, 4H).
Anal. Calcd for C19H24ClN5S: C, 58.52; H, 6.20; N, 17.96. Found: C, 58.40; H, 6.17; N,
17.86.
5.4.6 2-(4-Benzo[d]thiazol-2-yl-butyl)-1,2,3,4-tetrahydro-isoquinoline p-
toluenesulfonate (11)—The product was converted into the tosylate salt, followed by
crystallization from MeOH-Et2O to afford the pure compound. Yield (18%), mp: 154–155
°C; 1H NMR (DMSO-d6): δ 9.65 (brs, 1H), 8.05 (d, 1H, J = 7.8 Hz), 7.92 (d, 1H, J = 8.1
Hz), 7.49 (d, 1H, J = 7.5 Hz), 7.46-7.42 (m, 4H), 7.38 (d, 1H, J = 8.1 Hz), 7.29 - 7.19 (m,
3H), 7.14 (d, 4H, J = 7.5 Hz), 7.04-7.01 (m, 1H), 4.54 (d, 2H, J = 13.5 Hz), 4.28 (dd, 1H, J =
7.8, 15.6 Hz), 3.72-3.69 (m, 1H), 3.34-3.26 (m, 3H), 3.19-3.15 (m, 2H), 3.11-3.03 (m, 2H),
2.26 (s, 3H), 1.89-1.85 (m, 4H). Anal. Calcd for C34H38N2O6S3: C,61.24; H, 5.74; N, 4.20.
Found: C, 61.23; H, 5.92; N, 4.12.
5.4.7 2-(4-(Isoindolin-2-yl)butyl)benzo[d]thiazole hydrochloride (12)—The
product was converted into the HCl salt, followed by crystallization from MeOH-Et2O to
give the pure compound. Yield (7%), mp: 188–190 °C; 1H NMR (DMSO-d6): δ 11.08 (s,
1H), 8.05 (dd, 1H, J = 0.9, 7.2 Hz), 7.91 (dd, 1H, J = 0.6, 7.8 Hz), 7.50-7.44 (m, 1H),
7.41-7.32 (m, 4H), 7.22 (s, 1H), 4.75 (dd, 2H, J = 5.7, 13.8 Hz), 4.45 (dd, 2H, J = 6.9, 13.8
Hz), 3.41 (q, 2H, J = 5.7 Hz), 3.17 (t, 2H, J = 6.6 Hz), 1.90-1.87 (m, 4H). Anal. Calcd for
C21H24ClN3S 2HCl 0.3H2O: C, 59.00; H, 5.73; N, 7.24. Found: C, 59.00; H, 5.73; N, 7.24.
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5.6 General alkylation procedure for compounds (13–23)
A mixture of 1-(4-chlorophenyl)piperazine (0.65 mmol), 1-(benzo[d]thiazol-2-yl)-5-
iodopentan-1-one (35) (0.84 mmol), K2CO3 (5.18 mmol), and CH3CN (15 mL) was heated
to reflux for 12-24 h. The mixture was cooled to room temperature and then loaded onto a
cartridge and purified by flash chromatography using EtOAc and hexane (9.5:0.5) to give
the desired products.
5.6.1. 1-(Benzo[d]thiazol-2-yl)-4-(4-(4-chlorophenyl)piperazin-1-yl)butan-1-one
hydrochloride (13)—The product was converted into the HCl salt, followed by
crystallization from MeOH-Et2O to give the pure compound. Yield (19%), mp: 251–253
°C; 1H NMR (CD3OD): δ 8.19-8.16 (m, 1H), 8.13-8.09 (m, 1H), 7.66-7.57 (m, 2H), 7.26 (d,
2H, J = 6.6 Hz), 7.03 (d, 2H, J = 7.2 Hz), 3.88-3.73 (m, 4H), 3.49 (t, 2H, J = 7.2 Hz),
3.39-3.31 (m, 4H), 3.19-3.06 (m, 2H), 2.30-2.25 (m, 2H). Anal. Calcd for C21H23Cl2N3OS
0.15MeOH: C, 56.96; H, 5.33; N, 9.42. Found: C, 57.13; H, 5.60; N 9.04.
5.6.2 1-(Benzo[d]thiazol-2-yl)-4-(4-phenyl-piperazin-1-yl)-butan-1-one (14)—
Yield (48%), mp: 160–161 °C; 1H NMR (CDCl3): δ 8.17 (d, 1H, J = 7.8 Hz), 7.94 (d, 1H, J
= 8.1 Hz), 7.59-7.54 (m, 1H), 7.53-7.48 (m, 1H), 7.26-7.20 (m, 2H), 6.84 - 6.80 (m, 3H),
3.27 (t, 2H, J = 6.6 Hz), 2.97-2.94 (m, 4H), 2.55-2.47 (m, 6H), 2.13-2.08 (m, 2H).
Anal.Calcd for C21H23N3OS: C, 69.10; H, 6.34; N, 11.50. Found: C, 68.89; H, 6.31; N,
11.37.
5.6.3. 1-(Benzo[d]thiazol-2-yl)-4-(4-phenyl-piperidin-1-yl)-butan-1-one
hydrochloride (15)—The product was converted into the HCl salt, followed by
crystallization from MeOH-Et2O to afford the pure compound. Yield (48%), mp: 269–270
°C; 1H NMR (DMSO-d6): δ 10.37 (brs, 1H), 8.27-8.22 (m, 2H), 7.69 -7.67 (m, 2H),
7.34-7.30 (m, 2H), 7.24-7.19 (m, 3H), 3.58 (d, 2H, J = 14.7 Hz), 3.44-3.37 (m, 2H),
3.20-3.14 (m, 2H), 3.09-2.99 (m, 2H), 2.86-2.78 (m, 1H), 2.20-2.08 (m, 2H), 2.08-2.04 (m,
2H), 1.98-1.93 (m, 2H). Anal. Calcd for C22H25ClN2OS: C, 65.90; H, 6.28; N, 6.99. Found:
C, 65.70; H 6.22; N, 6.86.
5.6.4. 1-(Benzo[d]thiazol-2-yl)-4-(4-pyrimidin-2-yl-piperazin-1-yl)-butan-1-one
hydrochloride (16)—The product was converted into the HCl salt, followed by
crystallization from MeOH-Et2O to afford the pure HCl salt. Yield (42%), mp: 242–243
°C; 1H NMR (DMSO-d6): δ 10.76 (brs, 1H), 8.42 (d, 2H, J = 4.8 Hz), 8.26-8.21 (m, 2H),
7.69-7.60 (m, 2H), 6.75 (t, 1H, J = 4.8 Hz), 4.68 (d, 2H, J = 14.1 Hz), 3.64-3.58 (m, 2H),
3.47-3.34 (m, 4H), 3.24-3.17 (m, 2H), 3.06-3.01 (m, 2H), 2.162.11 (m, 2H). Calcd for
C19H23Cl2N5OS: C 51.82, H 5.26, N 15.90; Found: C 51.86, H 5.35, N 15.77.
5.6.5 1-(1-(5-(Benzo[d]thiazol-2-yl)-5-oxopentyl)piperidin-4-yl)-5-chloro-1H-
benzo[d]imidazol-2(3H)-one (17)—Yield (49%), mp: 221–222 °C; 1H NMR (DMSO-
d6) : δ 10.99 (s, 1H), 8.24-8.21 (m, 2H), 7.64-7.60 (m, 2H), 7.12 (d, 1H, J = 8.7 Hz),
6.96-6.90 (m, 2H), 4.04-4.16 (m, 1H), 3.28 (t, 4H, J = 8.4 Hz), 3.00-2.97 (m, 2H), 2.44-2.30
(m, 2H), 2.27-2.19 (m, 2H), 2.10-2.00 (m, 2H), 1.76-1.68 (m, 2H), 1.63-1.52 (m, 4H). Anal.
Calcd for C24H25ClN4O2S: C, 61.46; H, 5.37; N, 11.95. Found: C, 61.16; H, 5.45; N, 11.66.
5.6.6. 8-(5-(Benzo[d]thiazol-2-yl)-5-oxopentyl)-1-phenyl-1,3,8-
triazaspiro[4.5]decan-4-one (18)—Yield (60%), mp: 206–207 °C; 1H NMR (DMSO-
d6) : δ 8.58 (s, 1H), 8.24-8.19 (m, 2H), 7.63-7.60 (m, 2H), 7.17 (t, 2H, J = 8.4 Hz), 6.81 (d,
2H, J = 7.8 Hz), 6.69 (t, 1H, J = 7.2 Hz), 4.54 (s, 2H), 3.29 (t, 4H, J = 6.6 Hz), 2.80-2.54 (m,
4H), 2.36 (t, 2H, J = 7.2 Hz), 1.80-1.70 (m, 2H), 1.58-1.52 (m, 4H). Anal. Calcd for
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C25H28N4O2S 0.075 EtOAc: C, 65.97; H, 6.20; N, 12.31. Found: C, 65.99; H, 6.37; N,
12.03
5.6.7. 1-(Benzo[d]thiazol-2-yl)-5-(isoindolin-2-yl)pentan-1-one hydrochloride
(19)—The product was converted into the HCl salt, followed by crystallization from
MeOH-Et2O to give the pure compound. Yield (29%), mp: 248–250 °C; 1H NMR (DMSO-
d6): δ 11.36 (s, 1H), 8.22-8.19 (m, 2H), 7.64-7.60 (m, 2H), 7.32-7.24 (m, 4H), 4.37 (s, 4H),
3.33 (t, 2H, J = 6.6 Hz), 3.20 (brs, 2H), 1.75 (t, 4H, J = 2.7 Hz). Calculated for
C20H21ClN2OS: C, 64.42; H, 5.68; N, 7.51; Found: C, 64.51; H, 5.92; N, 7.31.
5.6.8. 1-(Benzo[d]thiazol-2-yl)-5-(4-(4-chlorophenyl)piperazin-1-yl)pentan-1-one
hydrochloride (20)—The product was converted into the HCl salt, followed by
crystallization from MeOH-Et2O to give the pure compound. Yield (58%), mp; 227–229
°C; 1H NMR (CD3OD) : δ 8.18-8.15 (m, 1H), 8.12-8.09 (m, 1H), 7.65-7.56 (m, 2H), 7.26
(d, 2H, J = 6.6 Hz), 7.00 (d, 2H, J = 6.6 Hz), 3.85 (d, 2H, J = 14.1 Hz), 3.70 (d, 2H, J = 12.6
Hz), 3.39 (t, 2H, J = 6.9 Hz), 3.32-3.22 (m, 6H), 3.19-3.04 (m, 2H), 1.93-1.90 (m, 4H).
Anal. Calcd for C22H26Cl3N3OS: C, 54.27; H, 5.38; N 8.63. Found: C, 54.35; H, 5.12; N
8.90.
5.6.9 1-(Benzo[d]thiazol-2-yl)-5-(4-pyrimidin-2-yl-piperazin-1-yl)-pentan-1-one
hydrochloride (21)—The product was converted into the HCl salt, followed by
crystallization from MeOH-Et2O to give the pure compound. Yield (35%), mp: 202–203
°C; 1H NMR (DMSO-d6): δ 11.06 (brs, 1H), 8.41 (d, 2H, J = 4.8 Hz), 8.25-8.21 (m, 2H),
7.68-7.61 (m, 2H), 6.74 (t, 1H, J = 4.8 Hz), 4.65 (d, 2H, J = 7.8 Hz), 3.54-3.50 (m, 2H),
3.47-3.38 (m, 2H), 3.34-3.30 (m, 2H), 3.17-3.11 (m, 2H), 3.05-2.94 (m, 2H), 1.87-1.82 (m,
2H), 1.79-1.71 (m, 2H). Anal. C20H25Cl2N5OS: C, 52.86; H, 5.55; N, 15.41. Found: C,
52.66; H, 5.66; N, 15.36.
5.6.10. 1-(Benzo[d]thiazol-2-yl)-5-(4-phenyl-piperazin-1-yl)-pentan-1-one
hydrochloride (22)—The product was converted into the HCl salt, followed by
crystallization from MeOH-Et2O to give the pure compound. Yield (37%). mp: 216–217
°C; 1H NMR (DMSO-d6): δ 10.85 (brs, 1H), 8.26-8.22 (m, 2H), 7.68-7.59 (m, 2H), 7.24
(dd, 2H, J = 7.2, 8.7 Hz), 6.97 (d, 2H, J = 7.8 Hz), 6.84 (t, 1H, J = 7.2 Hz), 3.80-3.77 (m,
2H), 3.55-3.52 (m, 2H), 3.35-3.31 (t, 2H, J = 6.6 Hz), 3.17-3.07 (m, 6H), 1.85-1.81 (m, 2H),
1.78-1.71 (m, 2H). Anal. Calcd for C22H26ClN3OS 0.7H2O: C, 61.65; H, 6.11; N, 9.80.
Found: C, 61.82; H, 6.45; N 9.62.
5.6.11. 1-(Benzo[d]thiazol-2-yl)-5-(4-phenyl-piperidin-1-yl)-pentan-1-one
hydrochloride (23)—The product was converted into the HCl salt, followed by
crystallization from MeOH-Et2O to give the pure compound. Yield (39%), mp: 204–205
°C; 1H NMR (DMSO-d6): δ 10.71 (brs, 1H), 8.26-8.22 (m, 2H), 7.68-7.59 (m, 2H),
7.34-7.29 (m, 2H), 7.23-7.18 (m, 3H), 3.54-3.51 (m, 2H), 3.30-3.24 (m, 2H), 3.12-3.05 (m,
2H), 2.93-3.01 (m, 2H), 2.83-2.75 (m, 1H), 2.02 – 2.15 (m, 2H), 1.90-1.94 (m, 2H),
1.88-1.82 (m, 2H), 1.77-1.70 (m, 2H). Anal. Calcd for C23H28Cl2N2OS: C, 66.57; H, 6.56;
N, 6.75. Found: C, 66.37; H, 6.56; N, 6.77.
5.7. Receptor binding studies
Binding affinities reported in Tables 1–4 were conducted by the National Institute of Mental
Health Psychoactive Drug Screening Program (NIMH-PDSP). Details of the methods and
radioligands used for the binding assays were previously reported [22].
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• Four old and 17 new benzothiazoles have been synthesized and screened for
binding to CNS receptors related to neuropsychiatric illnesses.
• Several benzothiazoles have been identified as potential leads in the
development of dual-acting agents at 5HT1A and SERT sites.
• One of the identified agents has little or no binding to receptors implicated in the
off-target pharmacology of known SSRIs and thus will undergo an elaborate
SAR studies.
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Synthesis of Target Compounds 7–12. Reagents and conditions: (i) Toluene, rt; (ii) KI,
K2CO3, CH3CN, reflux.
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Synthesis of Target Compounds. Reagents and conditions: (i) KI, K2CO3, CH3CN, reflux.
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Synthesis of alkylating agents, 34 and 35. Reagents and conditions: (i) n-BuLi, −78 °C,
THF; (ii) TPP, imidazole, I2, DCM, 0 °C - rt.
Zhu et al. Page 15














Synthesis of Target Compounds. Reagents and conditions: (i) KI, K2CO3, CH3CN, reflux.
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